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Background: Exercise reduced tolerance and breathlessness are common in the elderly and can result in
substantial loss in functionality and health related quality of life. Heart failure (HF) and chronic obstructive
pulmonary disease (COPD) are common underlying causes, but can be difficult to disentangle due to overlap in
symptomatology. In addition, other potential causes such as obesity, anaemia, renal dysfunction and thyroid
disorders may be involved.
We aim to assess whether screening of frail elderly with reduced exercise tolerance leads to high detection rates of
HF, COPD, or alternative diagnoses, and whether detection of these diseases would result in changes in patient
management and increase in both functionality and quality of life.
Methods/Design: A cluster randomized diagnostic trial. Primary care practices are randomized to the diagnostic-
treatment strategy (screening) or care as usual.
Patient population: Frail (defined as having three or more chronic or vitality threatening diseases and/or receiving
five or more drugs chronically during the last year) community-dwelling persons aged 65 years and older selected
from the electronic medical files of the participating general practitioners. Those with reduced exercise tolerance or
moderate to severe dyspnoea (≥2 score on the Medical Research Counsel dyspnoea scale) are included in the
study.
The diagnostic screening in the intervention group includes history taking, physical examination,
electrocardiography, spirometry, blood tests, and echocardiography. Subsequently, participants with new diagnoses
will be managed according to clinical guidelines. Participants in the control arm receive care as usual. All
participants fill out health status and other relevant questionnaires at baseline and after 6 months of follow-up.
Discussion: This study will generate information on the yield of screening for previously unrecognized HF, COPD
and other chronic diseases in frail elderly with reduced exercise tolerance and/or exercise induced dyspnoea. The
cluster randomized comparison will reveal whether this yield will result in subsequent improvements in functional
health and/or health related quality of life.
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Reduced exercise tolerance and exercise induced dys-
pnoea are very common complaints in the elderly, with
prevalence rates varying from 20% to 60% [1,2]. In many
of the elderly with these complaints heart failure (HF)
and/or chronic obstructive pulmonary disease (COPD)
may be involved [2]. Multiple causes, however, should be
considered, including obesity, anaemia, renal dysfunction
and thyroid disorders.
Because of overlap in clinical presentation [3-5], it is dif-
ficult to disentangle HF and COPD in the clinical assess-
ment, resulting in both false-negative and false-positive
diagnoses of both diseases in primary care [6-10], with
subsequent undertreatment and unnecessary drug therapy,
respectively. We suspect that especially in the frail, i.e.
those prescribed multiple drugs and with multimorbidity,
the prevalence of ‘unrecognized’ underlying disease caus-
ing reduced exercise is potentially high. For both COPD
and HF, but also for other possible underlying diseases
such as anaemia and thyroid disorders, effective interven-
tions (i.e. life style interventions and drugs) are available
that can improve symptoms, functionality and quality of
life and may reduce hospital admissions and mortality
[4,11]. Potentially, a substantial beneficial effect in health
outcome can be achieved by performing diagnostic tests
(screening) in the early course of these diseases.
We designed a cluster randomized trial to examine
whether screening frail elderly for HF, COPD, and easy to
detect other diseases (such as renal dysfunction, anaemia
and thyroid disorders) yields a high proportion of previ-
ously unrecognized disease and whether subsequent tar-
geted interventions improves patient outcome. Moreover,
we will assess whether such a strategy is cost-effective.
Key objectives
– To determine the yield of screening for previously
unrecognized HF, COPD and other chronic diseases
(like anaemia, renal dysfunction, thyroid disorders)
in frail elderly with reduced exercise tolerance and/
or exercise induced dyspnoea.
– To assess the effect of the diagnostic screening and
subsequent targeted interventions on functional
health and health related quality of life after
6 months of follow-up.
– To assess the cost-effectiveness of screening and
subsequent targeted management.




A cluster randomized trial with primary care practices at
the unit of randomization, comparing the effects of thescreening program (with subsequent targeted interven-
tions in newly detected diseases) compared to usual care
on the number of previously unrecognized chronic dis-
eases and on patient outcomes and costs. See Figure 1
for the study scheme.Study population and recruitment
Patients aged 65 years or over are selected from the elec-
tronic medical file of the participating general practi-
tioners (GPs). All participants are recruited by GPs from
the catchment area of the ‘network Utrecht care for
elderly (NUZO)’. In the Netherlands all citizens are
registered with a GP, irrespective of (co)treatment by a
specialist, including patients living in a home for the
elderly, but except those living in a nursing home or
hospice. Our sample can therefore be considered as a
representative sample of community dwelling patients
aged 65 year or over.
To identify frail elderly we will use the criteria of the
‘transition project Elderly Care Mid Utrecht (Om-U)’; i.
e. men or women who are chronically prescribed five or
more different types of drugs during the last year, and/or
have three or more chronic or life-threatening diseases.
Patients already known with an established diagnosis
of COPD (according to the GOLD-criteria [11]) AND
also known with established HF (i.e. diagnosed by a car-
diologist, backed-up by an echocardiogram [4]) are
excluded. Patients who are unable to travel to the sur-
gery of the GP or with severe cognitive problems are
also excluded.
The participating GP sends a letter to all eligible frail
patients, including an information letter about the study.
Patients willing to participate fill out two short question-
naires concerning dyspnoea and exercise tolerance.
Those who scored positive on reduced exercise tolerance
or had a ≥2 score on the Medical Research Counsel
(MRC) dyspnoea scale [12] are included in the study
(see Additional file 1 for an overview of the inclusion
criteria).
Written informed consent is obtained at the first ap-
pointment before any study procedure is undertaken.Randomization
Primary care practices are randomly allocated to either
the diagnostic screening with subsequent targeted inter-
vention strategy or care as usual. Randomization is con-
sidered necessary because we aim to quantify the clinical
effectiveness of the strategy (test results followed by tar-
geted treatment initiated by the GP). Cluster
randomization is used to avoid contamination of GPs
and participants between the two groups, which can























Randomized (18 general practices)
Allocated to screening: 8 practices
((S=5, M=1, L=2),
N= 5369 patients 65 years or older)
Allocated to care as usual: 10 practices
((S=6, M=2, L=2),
N= 6470 patients 65 years or older)
1811 frail patients 65 years or older 2331 frail patients 65 years or older 
Excluded:
3692 not frail












995 not willing to participate
657 no response*
395 frail patients 65 years or older with 
reduced exercise tolerance and/or exercise 
induced dyspnoea
446 frail patients 65 years or older with 
reduced exercise tolerance and/or exercise 
induced dyspnoea
Questionnaires: MDS and SF36
Screening with history taking, PE, blood 
tests, ECG, spirometry, echocardiography, 
VAS
Questionnaires: MDS and SF36
- Fill out MDS, SF36 and MRC
- Check of GPs files for new diagnoses 
and medication changes
- Panel evaluation for definite diagnosis
- Fill out MDS, SF36 and MRC
- Check of GPs files for new diagnoses 
and medication changes
Figure 1 Study scheme. S = small (2400 patients), M=medium (4800 patients), L = large (7200 patients), COPD= chronic obstructive pulmonary
disease, HF = heart failure, MDS=Minimal Data Set, SF36 = 36 Item Short-Form Health status questionnaire, PE = physical examination,
ECG= electrocardiogram, VAS = visual analog scale, MRC=Medical Research Council dyspnoea questionnaire, GP = general practitioner, #other
includes cognitive problems (like dementia) and unable to travel to the general practice, *after sending 2 written invitations.
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gram, using the minimization method. Minimization is
based on the size of the general practice (number of
enlisted men and women) and ensures that the two arms
are balanced in the number of participants.
Sample size
We estimated that with our diagnostic strategy at least 15%
of the population under study would be diagnosed with
newly detected HF and/or COPD. These numbers are
based on previous diagnostic studies showing that among
elderly with COPD 20% had previously unknown HF [6].
To detect a 10% difference between the 2 arms in
diagnoses of HF and/or COPD, using an alpha of 0.05, a
power of 0.80 and an intracluster correlation coefficient
of 0.05[13], 301 participants per arm are needed. Con-
sidering a drop-out of 10% we aim to include 400participants in each arm (total 800). We calculated that
around 35 general practices should participate to recruit
800 participants.
Study procedures
At the first appointment, all participants fill out a ques-
tionnaire of the ‘Dutch National Care for the Elderly
Program (ZonMw-NPO)’, i.e. the Minimal Data Set
(MDS)[14] on functionality and a questionnaire on gen-
eral health related quality of life, i.e. the short form-36
(SF-36) [15,16].
Subsequently, participants receive detailed information
on the study procedures in the diagnostic screening
strategy arm or care as usual arm, depending on the ran-
dom allocation of their GP practices.
After six months the electronic medical files of all parti-
cipants are searched to document changes in medication
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months and participants are asked to fill out again the
MRC dyspnoea, MDS and SF-36 questionnaires.
Screening strategy and care as usual
The diagnostic screening includes the following tests:
standardized questionnaire on medical history, symp-
toms and current drug use (participants are asked to
bring their medication containers), physical examination
with special attention for the heart and lungs, blood
tests, electrocardiogram (ECG), spirometry with pre-
and post-bronchodilator measurements and echocardi-
ography including tissue Doppler imaging.
The physical examination is performed by a trained
physician in a standardized manner. Venous blood sam-
ples are taken and after centrifugation specimens of
plasma and cells will be stored at −70 degrees Celsius.
The blood tests include measurements of plasma B-type
natriuretic peptide measurements (NT-pro-BNP), glu-
cose levels, creatinin levels (with a calculated estimated
glomerular filtration rate (eGFR) according to MDRD
(modification of diet in renal disease)), haemoglobin and
Thyroid-Stimulating Hormone (TSH) levels. A standard
12-lead ECG is recorded by a trained employee of the
GPs’ laboratory (Saltro) and classified according to the
Minnesota coding criteria by a single cardiologist,
blinded to all other test results [17].
The spirometry is also performed by a trained em-
ployee of Saltro before and 20 minutes after administra-
tion of ipratropiumbromide inhalation with an
inhalation chamber, and subsequently read and inter-
preted by a pulmonologist.
Echocardiography is performed with a mobile echocar-
diography (Vivid-i) by a trained and experienced cardiac
sonographer from Saltro. All echocardiographic images
will be stored and interpreted by a single cardiologist
who is blinded to all other data.
After every investigation, the participant fills out a vis-
ual analog scale (VAS) to measure the burden experi-
enced during the investigation (0 = not burdening at all,
10 = extremely burdening).
All investigations take place in the patient’s general prac-
tice office. Every participant in the diagnostic screening
group receives all measurements. About two weeks after
the investigations, the GP of the participant in the diag-
nostic screening arm will receive all results, with (prelim-
inary) diagnoses (presence or absence of HF and/or COPD
and of other diseases) including a treatment advice. The
GP can then initiates or adjusts the treatment according to
current clinical guidelines.
In the care as usual group, the participating GP only
receives the answers to the questionnaires about symp-
toms (answers to the MRC dyspnoea and exercise toler-
ance questionnaires) from the participants. It is up tothe GP to decide whether he/she actively starts any




The presence of HF and/or COPD present or absent will
be determined six months after the initial investigations
by an outcome panel that will evaluate all diagnostic test
results and the effect of treatment during six months
follow-up.
For the diagnosis of COPD, airflow obstruction with
spirometry is a prerequisite and defined as a post-
dilatory ratio of the forced expiratory volume in one sec-
ond (FEV1) to the forced vital capacity (FVC) <0.70
(FEV1/FVC ratio <0.70). To classify the severity of ob-
struction, the GOLD-criteria [11] will be applied by the
panel.
For the diagnosis of HF, the panel applies the criteria
of the European Society for Cardiology (ESC) [4]. HF is
considered present when participants have suggestive
symptoms (i.e. breathlessness at rest or on exercise, fa-
tigue, tiredness, ankle swelling) and signs (i.e. pulmonary
rales, raised jugular venous pressure, peripheral oedema,
laterally displaced apical beat) in combination with ob-
jective echocardiographic evidence of cardiac dysfunc-
tion at rest. In participants who use diuretics for
hypertension, signs of volume overload could be masked
and therefore in these participants signs of fluid overload
are not obligatory. Participants classified as HF by the
panel will further be classified as systolic HF, heart fail-
ure with preserved ejection fraction (HFPEF) or right-
sided HF (cor pulmonale).
For systolic HF, participants need to have a left ven-
tricular ejection fraction (LVEF) ≤45%. To diagnose
HFPEF, there must be echocardiographic evidence of
diastolic structural or functional abnormalities (abnor-
mal left ventricular relaxation or diastolic stiffness), left
atrial enlargement or left ventricular hypertrophy (LVH)
in combination with a LVEF >45% [18]. Participants
with echocardiographically-determined LVH and an
indexed left atrial volume of ≥34 ml/m2 or tissue Dop-
pler abnormal mitral inflow or pulmonary venous flow
profile are also classified as having diastolic dysfunction.
In participants with atrial fibrillation (AF) a complete
diastolic assessment is not feasible and therefore we
consider an elevated indexed LA volume sufficient to
classify diastolic dysfunction in participants with AF.
Isolated right-sided HF is defined as increased pulmon-
ary artery pressure (calculated systolic pulmonary artery
pressure >40 mmHg) and a LVEF >45%.
The panel also assessed the most likely cause of HF
based on the information from the investigations of the
diagnostic screening.
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Other new diagnoses considered as an explanation of
reduced exercise tolerance or dyspnoea are (persisting)
asthma, pulmonary restriction, obesity, anaemia, renal
dysfunction, thyroid disorders and atrial fibrillation.
For the diagnosis asthma a combination of symptoms
(dyspnoea, wheezing, coughing, sputum production), al-
lergy and/or hyperreactivity is needed, and an increase
of >12% in forced expiratory volume in one second
(FEV1) from pre- to post-dilatory measurements further
confirms the diagnosis. The diagnosis of pulmonary re-
striction is based on a post-dilatory forced vital capacity
(FVC) post-dilatory< 80% of predicted, in the absence
of a diagnoses of COPD.
Obesity is defined as a body mass index (BMI) above
30 kg/m2.
Anaemia is considered present if Haemoglobin (Hb) is
below 7.0 mmol/l in women and below 8.0 mmol/l in
men aged 65 to 69 years. In patients aged 70 years or
over anaemia is present if Hb is below 6.9 mmol/l in
men and below 6.8 mmol/l in women.
Renal dysfunction is considered present if the calcu-
lated, based on the MDRD formula, eGFR is below
90 ml/min/1.73 m2 for men and 80 ml/min/m2 for
women. Severity of renal dysfunction is divided into 4
stages; mild (GFR between 60 ml/min/1.73 m2 and 80
(women) or 90 (men), moderate (GFR between 30 and
59 ml/min/1.73 m2), severe disease (GFR between 15
and 30 ml/min/1.73 m2) and kidney failure (GFR below
15 ml/min/1.73 m2) [19].
Thyroid disorders are divided into hypo- or hyperthy-
roidism. When the Thyroid-Stimulating Hormone (TSH)
level is below 0.35 or above 5.5 mu/l, Free Thyroxin 4
(FT4) will be measured. Hypothyroid disease is consid-
ered present when TSH >5.5 mu/l and FT4 <11 pmol/l.
Subclinical hypothyroid disease is when TSH >5.5 mu/l,
and FT4 within normal limits (i.e. between 11 and 23
pmol/l). Hyperthyroid disease is considered present
when TSH <0.35 mu/l and FT4 >23 pmol/l. Subclinical
hyperthyroid disease is a TSH <0.35 mu/l and FT4
within normal limits.
Atrial fibrillation is classified according to the Minne-
sota coding [17].
Functional health
Functional health is measured with the Minimal Data
Set (MDS). The dimensions asked in the MDS are: living
situation, perceived health and quality of life, health
related quality of life (questions of the index EuroQol
Five-Dimensional Questionnaire (EQ-5D_index))[20],
activities of daily living (ADL) functioning (questions
from Katz-15[21]) and health care use (hospital admis-
sions, visits of GP outside office hours, home care and
temporally admission to a nursing home).Health related quality of life
Health related quality of life is measured by the SF-36
and the EQ-5D_index (included in the MDS) question-
naires. The SF-36 is divided into nine subscales: physical
functioning, social functioning, limitations in usual role
activities due to physical problems, limitations in usual
role activities due to emotional problems, bodily pain,
change in health, general mental health and vitality
health change and general health perception. Scores
range from 0 and 100.
The EQ-5D_index is a questionnaire with five dimen-
sions (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression), which are divided into
three degrees of severity, ‘no problem’, ‘some problems’
or ‘major problems’. A single index score can be pro-
duced using information from these five dimensions.
Higher scores are associated with a better health
related quality of life.
Costs
The electronic medical file from the GP is used to col-
lect information about direct costs during the follow-up
period of 6 months. Information about GP visits, investi-
gations (i.e. blood tests, ECG, spirometry), outpatient
visits, hospitalizations and medication use are collected
in both groups. In the diagnostic screening group add-
itionally costs are calculated for all performed test at
baseline. Prices will be based on market prices or tariffs.
Final diagnosis by the panel
The final diagnoses are set by a joint panel consisting of
three members, a cardiologist, a pulmonologist and a
GP. Consensus diagnosis by the panel will be our refer-
ence test for the diagnosis of COPD and HF, in case of
any discongruence with the classification described be-
fore. This is an established method in case an irre-
proachable reference standard is lacking, as is the case
for HF [22]. In case of no consensus the majority deci-
sion will be used. In analogy with earlier studies, the
panel will use all available information from the diagnos-
tic and follow-up results: the latter to include the effect
of targeted therapy in the decision whether a disease is
present. The reproducibility of the panel diagnoses will
be evaluated by re-testing a random sample of 10% by
the same outcome panel.
The joint panel evaluation is divided in three steps;
step 1 history taking, physical examination, blood tests,
ECG and spirometry, step 2 adding NT-pro-BNP and
step 3 adding echocardiography and follow-up. After
step 1 and 2 the panel gives a percentage (0-100%) of
their suspicion for the different outcomes. With this, we
can evaluate how the panel reaches their final diagnoses
(set at step 3) and which investigations add most in
reaching this decision.
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a pulmonologist and a cardiologist, but the procedure is
changed slightly by dividing step 3 in two steps whereby
step 3 includes only echocardiography and at step 4 the
follow-up is included and the final diagnoses are made.
We will evaluate this individual approach and compare
it with the more time consuming joint panel evaluation.Blinding
In our single blind study we apply no active measures
for blinding the group assignment. The GPs are invited
to participate in a study detecting unrecognized HF and
COPD. If they agree to participate, their practice is ran-
domized and they receive detailed information. This
strategy of selective information is chosen to avoid that
GPs in the control group perform all diagnostic tests
available in the diagnostic screening program.
Participants will be aware whether their GP practice is
allocated to the diagnostic screening arm or to usual
care. Researchers are not blinded. There is no risk in ob-
server bias for the outcome, because the questionnaires
used to collect outcome measurements are filled out at
home by the participants themselves.Statistical analyses
The yield of previously unrecognized HF and COPD
(and other diseases) will be calculated as a proportion
with 95% confidence intervals in both arms of the trial.
The absolute difference in yield between the arms will
then be calculated together with its 95% confidence
interval. We will also calculate how many participants in
the diagnostic screening group were initially incorrectly
diagnosed with COPD or HF.
The difference in functional health and quality of life be-
tween the diagnostic screening and care as usual groups at
6 months will be compared taking into account potential
baseline difference of relevant parameters at baseline
(ANCOVA), although such differences are expected to be







Age (years), mean (sd) 75.6 ± 6.9 74.6 ± 6.3
Male sex, n (%) 1956 (47.2%) 419 (49.8
Co-morbidities (number), median (IQR) 3 (3–4) 3 (3–4)
Drugs (number), median (IQR) 5 (4–7) 6 (4–7)
#All selected frail patients aged 65 years or over, *patients who were willing to part
answer on questionnaire about reduce exercise tolerance), <patients who were will
score ≤1 and only negative answers on the questionnaire about reduce exercise to
response after sending 2 written invitations. {P=<0.05 compared to the patients w
in the study (no dyspnoea, not willing and no response), •p=<0.05 dyspnoea compMultivariable regression analysis with receiver operating
characteristic (ROC) curves and percentages correctly
diagnosed participants will be used to analyze which of
the test used in the diagnostic screening are most predict-
ive or necessary for setting the diagnosis of HF and COPD
in the study group. A multilevel approach is used in the
analyses to correct for the fact that we randomized at the
GP practice and not at the patient level.Cost-effectiveness analysis
The cost-effectiveness of the diagnostic strategy for detec-
tion and treatment of (previously unrecognized) HF and
COPD (diagnostic screening group) is evaluated and com-
pared with care as usual. Cost-effectiveness is expressed in
terms of cost per case of COPD and per case of HF
detected, and in terms of cost per Quality Adjusted Life
Years gained (Cost-utility analysis). For measuring direct
cost, resource quantities are collected prospectively
through the electronic medical files from the GPs. Prices
are based on market prices or tariffs for the investigations
performed under study. Relevant indirect medical costs
are taken into account such as participant time invested
and travel costs. As the population under study is older
than 65 years of age, productivity losses will not be stud-
ied. Sensitivity analysis and multivariate uncertainty ana-
lysis are performed, conform current Dutch standards for
pharmaco-economic research [23].Regulation statement
This study is conducted according to the principles of
the current version of the declaration of Helsinki and in
accordance with the Dutch law on Medical Research In-
volving Human Subjects Act (WMO).Ethics committee approval
The study was approved by the medical ethical commit-
tee (METC) of the University Medical Center Utrecht
(UMCU), the Netherlands.s and non-responders)





(n= 408) (n= 1774) (n= 1119)
• 73.8 ± 6.1{ 76.3 ± 7.0{ 75.9 ± 7.2{
%)† 270 (66.2%){ 763 (43.0%){ 504 (45.0%){
3 (3–4) 3 (3–4) 3 (3–4)
5 (3–6) 5 (4–7) 6 (4–7)
icipate and fully met the inclusion criteria (MRC dyspnoea ≥2 and/or a positive
ing to participate, but were excluded based on complaints (MRC dyspnoea
lerance), ^patients who were not willing to participate, >patients who gave no
ith dyspnoea, †p=ns dyspnoea patients compared to patients not participating
ared to patients not participating in the study.
Table 2 Baseline characteristics
All Diagnostic screening Care as usual
(n= 841) (n= 395) (n= 446)
Mean age in years ± sd 74.6 ± 6.3 75.4 ± 6.2 73.8 ± 6.3
Male sex, n (%) 418 (49.7%) 176 (44.6%) 242 (54.3%)
Complaints
MRC Dyspnoea score, median (IQR) 2 (2–3) 2 (2–3) 2 (2–3)
Reduced exercise tolerance questionnaire score, median (IQR) 2 (1–3) 2 (0–3) 2 (1–3)
Cardiovascular co-morbidities
Ischemic heart disease, n (%) 259 (30.8%) 127 (32.2%) 132 (29.6%)
Heart failure, n (%) 42 (5.0%) 22 (5.6%) 20 (4.5%)
Valvular disorders, n (%) 59 (7.0%) 24 (6.1%) 35 (7.8%)
Cardiac rhythm disorders, n (%) 116 (13.8%) 55 (13.9%) 61 (13.7%)
Hypertension, n (%) 591 (70.3%) 292 (73.9%) 299 (67.0%)
Hypercholesterolemia, n (%) 234 (27.8%) 94 (23.8%) 140 (31.4%)
Diabetes Mellitus, n (%) 262 (31.2%) 130 (32.9%) 132 (29.6%)
CVA or TIA, n (%) 99 (11.8%) 44 (11.1%) 55 (12.3%)
Non-cardiovascular co-morbidities
Visual impairment, n (%) 207 (24.6%) 98 (24.8%) 109 (24.4%)
Hearing impairment, n (%) 93 (11.1%) 43 (10.9%) 50 (11.2%)
COPD, n (%) 134 (15.9%) 68 (17.2%) 66 (14.8%)
Asthma, n (%) 78 (9.3%) 36 (9.1%) 42 (9.4%)
Mood disorders, n (%) 27 (3.2%) 11 (2.8%) 16 (3.6%)
Urinary tract problems, n (%) 90 (10.7%) 35 (8.9%) 55 (12.3%)
Osteoporosis, n (%) 58 (6.9%) 25 (6.3%) 33 (7.4%)
Malignancies, n (%) 51 (6.1%) 18 (4.6%) 33 (7.4%)
Anaemia, n (%) 14 (1.7%) 9 (2.3%) 5 (1.1%)
Renal insufficiency, n (%) 47 (5.6%) 12 (3.0%) 35 (7.8%)
Thyroid dysfunction, n (%) 63 (7.5%) 28 (7.1%) 35 (7.8%)
Osteoarthritis, n (%) 212 (25.2%) 126 (31.9%) 86 (19.3%)
Co-morbidities (number), median (IQR) 3 (3–4) 4 (3–4) 3 (3–5)
Drugs
Diuretics, n (%) 346 (41.1%) 169 (42.8%) 177 (39.7%)
ACE-i/ARBs, n (%) 478 (56.8%) 220 (55.7%) 258 (57.8%)
ß-blockers, n (%) 397 (47.2%) 185 (46.8%) 212 (47.5%)
Digitalis, n (%) 20 (2.4%) 12 (3.0%) 8 (1.8%)
Oral anticoagulants, n (%) 117 (13.9%) 49 (12.4%) 68 (15.2%)
Platelet antagonists, n (%) 402 (47.8%) 192 (48.6%) 210 (47.1%)
Treatment for hypercholesterolemia 488 (58.0%) 209 (52.9%) 279 (62.6%)
Anti-diabetic drugs, n (%) 223 (26.5%) 109 (27.6) 114 (25.6%)
Treatment for COPD or Asthma, n (%) 204 (24.3%) 91 (23.0%) 113 (25.3%)
Drugs (number), median (IQR) 6 (4–7) 5 (4–7) 6 (4–7)
baseline characteristics at selection based on electronic medical fileI Ischemic heart disease includes prior myocardial infarction, angina pectoris, coronary artery
bypass grafting, and percutaneous coronary intervention; visual impairment includes cataract, blindness or glaucoma, ACE-i = angiotensin converting enzyme-
inhibitor, ARBs = angiotensin receptor blockers.
van Mourik et al. BMC Public Health 2012, 12:385 Page 7 of 9
http://www.biomedcentral.com/1471-2458/12/385
van Mourik et al. BMC Public Health 2012, 12:385 Page 8 of 9
http://www.biomedcentral.com/1471-2458/12/385Results of inclusion
Eighteen general practices are included in the study, 8
were randomized to the diagnostic screening interven-
tion and 10 to the care as usual group.
Of the 11.839 patients aged 65 years or older (16% of all
registered citizens) enlist with these practices, 35% met
the criteria of frailty. The mean age of the 4142 selected
frail patients is 75.6 (SD ±6.9) years and 47% is male. In
Table 1 patient characteristics, median number of co-
morbidities and medication is given for all selected
patients. Of the invited frail patients, 73% responded to
our invitation and 30% (1249) was willing to participate.
Of those frail patients willing to participate, 33% had no
complaints of reduced exercise tolerance or dyspnoea
(MRC< 2) and therefore are excluded from the study.
Patients excluded because they had no complaints were
younger (p= 0.04) and more often male (p=<0.001) as
compared to included patients. Eligible patients who
refused to participate (n= 3301) were slightly older
(p=<0.001), but they were comparable on gender
(p=0.09) compared to participants.
Finally, 841 frail patients with complaints of dyspnoea
or reduced exercise tolerance were included in the study:
24% with dyspnoea, 16% with reduced exercise tolerance
and 60% with both symptoms. The mean age of the parti-
cipants was 74.6 (SD ±6.3) years and 50% were male. Im-
portant co-morbidities were hypertension (70%), diabetes
mellitus (31%), ischemic heart disease (31%), hypercholes-
terolemia (28%), osteo-arthritis (25%) and visual impair-
ment (25%). The most frequently used drugs are related to
these co-morbidities. All baseline characteristics of the
included patients are described in Table 2.
In total 395 participants were included in the diagnos-
tic screening group and 446 in the care as usual group.
The distribution of co-morbidities and drug use of the
two arms are shown in Table 2.
Discussion
The screening arm of the trial will generate data on the
proportion of frail elderly with reduced exercise toler-
ance and/or exercise induced dyspnoea that have
unrecognized HF, COPD and other chronic diseases (like
anaemia, renal dysfunction, thyroid disorders). The com-
parison of the screened versus usual care arm within this
clustered randomized trial will reveal whether screening
and subsequent targeted interventions would be benefi-
cial for frail elderly with respect to functional health
and/or health related quality of life after 6 months of
follow-up. The cost-effectiveness will also be examined.
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